Abstract 5822
Background
The real life experience in clinical arena can be challenging for student nurses, to cope with the patients’ suffering, to provide care, to communicate with them and their caregivers as death approaches .It is essential to understand student nurses’ feelings when confronted a dying patient, so that specific training, consultation and empowerment give them prior to their clinical placement. However, there has been little research in Greece on student nurses’ experience when facing care of patients and their caregivers in the last days of life.The purpose of this study was to explore undergraduate student nurse’s experience facing death and dying of a patient during their clinical practice.
Methods
A qualitative, descriptive design was used. Qualitative data were collected in June 2018 from 4th -year nursing students’ of Nursing School of National and Kapodistrian University of Athens. Experiences were collected through written reflections to obtain data about their experience when cared for a serious ill patient and when delivered their care to a dying patient and their caregivers. A content analysis of their comments was carried out.
Results
From 101 undergraduated nurses 42 answered in open-ended question “Please describe the death experience of a patient during your clinical practice”. The response rate was 41,6%.The average age of the students was 22.Nursing students’ comments revealed concerns on handling the family/caregivers of the dying patient, their willingness to care for body of the dying, expressing their emotions such as sadness, describing death experience using medical terminology and using their previous personal experiences and knowledge to handle with . Thus five categories were emerged, the concept of “family/caregivers issues” “participation in the care of the dying” “description of the event using medical terminology”, “expressing emotions positive or negative” and “referring to their previous experience and knowledge” respectively.
Conclusions
Study’s findings highlighted the influence of knowledge, personal attitudes and clinical stressors that student nurses faced in a clinical practice when they were training in palliative care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract